ALNY
Alnylam Pharmaceuticals Inc

4,359
Loading...
Loading...
News
all
press releases
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·12d ago
News Placeholder
More News
News Placeholder
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Zacks·14d ago
News Placeholder
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to Alnylam Pharmaceuticals stock based on the movements in the options market lately.
Zacks·18d ago
News Placeholder
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Zacks·21d ago
News Placeholder
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
Zacks·25d ago
News Placeholder
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
Zacks·2mo ago
News Placeholder
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2mo ago
News Placeholder
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest ALNY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.